ArticleCureus2026
A Comparative Analysis of Liver Function Test Profiles in Alcoholic Versus Metabolic-Associated Steatotic Liver Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Liver function tests (LFTs) are essential for evaluating hepatic injury in steatotic liver disease. Alcoholic fatty liver disease (AFLD) and metabolic-associated steatotic liver disease (MASLD) share steatosis but differ in pathogenesis. This study aimed to compare LFT profiles between AFLD and MASLD to identify potentially distinct biochemical patterns. Methods This cross‑sectional study included 90 participants (30 AFLD, 30 MASLD, 30 healthy controls) at Krishna Institute of Medical Sciences, Karad, India. A comprehensive LFT panel was analyzed, including transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), alkaline phosphatase (ALP), bilirubin fractions, total protein, albumin, and globulin. AST/ALT and albumin/globulin (A/G) ratios were derived. Statistical analyses included analysis of variance (ANOVA) with post‑hoc Tukey honestly significant difference (HSD), chi‑square tests, and exploratory receiver operating characteristic (ROC) analysis. Given the small sample size, multivariable regression was not performed. Results Both disease groups showed significant LFT abnormalities compared to controls (p < 0.001). Mean total bilirubin was 0.88 mg/dL (15.0 μmol/L) in AFLD and 0.79 mg/dL (13.5 μmol/L) in MASLD, within normal limits. MASLD demonstrated higher ALT elevations (70 ± 25 U/L vs. 45 ± 15 U/L in AFLD, p < 0.05). The AST/ALT ratio >1.5 was present in 62% of AFLD versus 28% of MASLD (p < 0.001). Hypoalbuminemia was mild and likely multifactorial. Exploratory ROC analysis of the AST/ALT ratio yielded an area under the curve (AUC) of 0.88 (95% CI 0.82-0.94), suggesting potential discriminative value that requires external validation. Conclusion AFLD and MASLD exhibit suggestive LFT trends: MASLD shows a predominant hepatocellular injury pattern (high ALT and low AST/ALT ratio), while AFLD more often shows an elevated AST/ALT ratio with mild hypoalbuminemia. However, these patterns are not diagnostic, overlap exists, and validation in larger cohorts with objective alcohol biomarkers and fibrosis assessment is needed before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.